Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Infant Bacterial Therapeutics AB's 3-Year RORE % for the quarter that ended in Mar. 2026 was -17.57%.
FRA:9IB's 3-Year RORE % is ranked worse than 57.23% of 1293
companies
in the Biotechnology industry
Industry Median: -11.55
vs FRA:9IB: -17.57
Infant Bacterial Therapeutics AB (FRA:9IB) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Infant Bacterial Therapeutics AB 3-Year RORE % Related Terms
Infant Bacterial Therapeutics AB 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infant Bacterial Therapeutics AB 3-Year RORE % Chart
FRA:9IB vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infant Bacterial Therapeutics AB 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Infant Bacterial Therapeutics AB's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Infant Bacterial Therapeutics AB (FRA:9IB) has a 3-Year RORE % of -17.57 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Infant Bacterial Therapeutics AB and its competitors. According to the industry distribution chart, Infant Bacterial Therapeutics AB ranks #740 out of 1293 companies in the Biotechnology industry, placing it in the top 57.2%.
Is Infant Bacterial Therapeutics AB's 3-Year RORE % too high?
Infant Bacterial Therapeutics AB's current 3-Year RORE % is -17.57. Based on the distribution chart, Infant Bacterial Therapeutics AB ranks #740 out of 1293 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Infant Bacterial Therapeutics AB ranks #740 out of 1293 companies for 3-Year RORE %. This places Infant Bacterial Therapeutics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Infant Bacterial Therapeutics AB and its competitors. Infant Bacterial Therapeutics AB's current 3-Year RORE % is -17.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (FRA:9IB) has a current 3-Year RORE % of -17.57. The current 3-Year RORE % is -17.57. Infant Bacterial Therapeutics AB's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (FRA:9IB), the current 3-Year RORE % is -17.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Infant Bacterial Therapeutics AB Business Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
13GF Score
Get the complete analysis for FRA:9IB
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9IB has been successfully added to your 
